The company's high P/E ratio amid shrinking medium-term earnings is worrisome. The market's expected 42% growth next year highlights the company's recent earnings decline. The share price may drop further if business prospects don't significantly improve.
Despite a high rate of reinvestment, the low ROE suggests that this reinvestment is not benefiting its investors and is negatively impacting earnings growth. Caution is advised when dealing with this company.
Hainan Huluwa Pharmaceutical Group Stock Forum
No comment yet